Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EBIT (2016 - 2025)

Vistagen Therapeutics' EBIT history spans 13 years, with the latest figure at -$19.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 29.31% year-over-year to -$19.6 million; the TTM value through Dec 2025 reached -$69.9 million, down 32.3%, while the annual FY2025 figure was -$56.0 million, 69.51% down from the prior year.
  • EBIT for Q4 2025 was -$19.6 million at Vistagen Therapeutics, up from -$20.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$6.2 million in Q1 2021 and bottomed at -$20.1 million in Q3 2025.
  • The 4-year median for EBIT is -$12.1 million (2024), against an average of -$12.1 million.
  • The largest annual shift saw EBIT crashed 288.59% in 2021 before it dropped 27.61% in 2025.
  • A 4-year view of EBIT shows it stood at -$10.5 million in 2021, then increased by 25.19% to -$7.9 million in 2023, then plummeted by 91.78% to -$15.1 million in 2024, then dropped by 29.31% to -$19.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EBIT are -$19.6 million (Q4 2025), -$20.1 million (Q3 2025), and -$15.8 million (Q2 2025).